
Recursion Pharmaceuticals has secured FDA agreement on the design of its Phase 3 trial for REC-4881, an oral MEK1/2 inhibitor targeting familial adenomatous polyposis (FAP), a rare genetic disease with no approved drug treatments. The trial will enroll about 200 adults post-colectomy and use a novel primary endpoint including removal of adenomas ≥10 mm, which are linked to cancer risk. This milestone follows promising Phase 2 results showing significant polyp reduction. The trial is set to start in the second half of 2027, aiming to provide the first pharmacologic therapy for FAP patients who currently face lifelong surveillance and surgery.
Recursion Pharmaceuticals' stock is trading at USD 2.83 on Pluang as of Nov 18, 2026 17:11 WIB, closer to its 52-week low of USD 2.72 than its high of USD 4.96, indicating the price remains well below its peak despite recent positive news. The stock gained 4.04% in the last day, yet the majority of Pluang users, 87%, are selling rather than buying. This suggests cautious investor sentiment even as the company advances its Phase 3 trial plans.